linjc16/ctgov huggingface dataset:
Risk-taking, Self Control and Humor Styles

Study Overview
=================
Brief Summary
-----------------
Therefore, this study tries to examine relationships among risk perception, risk-taking and humor styles through the mediating role of self-control. The present study used the correlation method. The statistical population consisted of all undergraduate students from University of Bojnord. The number of 400 students from the Faculty of Humanities and Basic Sciences was selected by using cluster sampling. The questionnaires were distributed in the classes among who inclined to participate in this study and they completed the questionnaires as anonymous.

Official Title
-----------------
The Relationship of Risk Perceptions and Risk-taking With Humor Styles: Mediating Role of Self-control

Conditions
-----------------
Risk-Taking, Humor as Topic, Self-Control

Intervention / Treatment
-----------------
* Other: correlation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: be a student of the college Exclusion Criteria: Unwillingness to study And not being a student at university
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: correlation|the subjects completed the questionnaires|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-Control | variable self-control was measured by the self-control Questionnaire. it has 36 items that were rated on a 5-point scale (from 1 not at all like me to 5 very much like me). it was completed by the participants. | 2 days | 
| Humor styles | variable of humor style was measured by the Questionnaire of humor style. it HSQ included 32-item measures humor styles on a 7-point Likert scale ranging from strongly disagree (1)to strongly agree(7). HSQ measure the four humor styles of affiliative, self-enhancing, aggressive, and self-defeating. it was completed by the participants. | 2 days | 
| risk taking | the variable of risk-taking was measeured by Domain-Specific Risk-Taking (DOSPERT) scale. DOSPERT is 30- items that measure risks in 5 fields: health/safety, social, ethical, financial, and recreational. Each item is assessed twice, one time was rated items based on perceived risk and next time was rated same items based on likelihood engage in the risky. it was completed by the participants. Responses are give with using a 7-point rating scale ranging from1 (Extremely Unlikely) to 7 (Extremely Likely). Higher scores indicate greater risk taking in the domain of the subscale. the risk-perception scale evaluates the respondents' gut level assessment of how risky each behavior is on a7-point rating scale ranging from 1 (Not at all) to 7 (Extremely Risky). Ratings are again added across all items of a given subscale to obtain subscale scores, with higher scores suggesting perceptions of greater risk in the domain of the subscale | 2 days |
Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis

Study Overview
=================
Brief Summary
-----------------
This study will test whether addition of imiquimod to standard antimony therapy provides a significant benefit in subjects with newly diagnosed cutaneous leishmaniasis. Based on our previous results, we hypothesize that lesions in patients who receive the combined treatment of pentavalent antimony and imiquimod as a first line therapy will resolve more rapidly and produce less scarring than treatment with pentavalent antimony alone.

Official Title
-----------------
Randomized Double Blind Clinical Trial of Imiquimod (Aldara) Versus Placebo Used in Combination With Pentavalent Antimony (Glucantime) in Peruvian Cutaneous Leishmaniasis Patients

Conditions
-----------------
Cutaneous Leishmaniasis

Intervention / Treatment
-----------------
* Drug: Imiquimod


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males/Females between 5 and 65 yrs CL diagnosis confirmed >4 weeks time disease no prior anti-leishmanial therapy for CL negative pregnancy test informed written consent or parent consent for <18yrs patients Exclusion Criteria: >25cm2 lesion(s) >6 cutaneous lesions mucosal lesion previous exposure to Imiquimod or anti-leish treatment participation in another protocol within 30 days prior study other acute or chronic illness / medication that may interfere significant psychiatric illness anaphylaxis or severe allergic reaction to proposed drugs patients unlikely to cooperate concomitant infection pregnancy or breast feeding

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Imiquimod|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to healing |  |  | 
| Reduction of scaring |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety (measured by AE reporting) during treatment and follow up to 12 months |  |  |
Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
This study is conducted in Europe and Asia. The aim of this observational study is to evaluate the effectiveness and the incidence of serious adverse reactions while using Levemir®, NovoMix® and/or NovoRapid® in subjects with type 2 diabetes that have not used insulin previously under normal clinical practice conditions.

Official Title
-----------------
Evaluation of Effectiveness and Safety of Levemir® (Insulin Detemir), NovoMix® (Biphasic Insulin Aspart) and/or NovoRapid® (Insulin Aspart) in Insulin naïve Subjects With Type 2 Diabetes.

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: insulin detemir
* Drug: biphasic insulin aspart 30
* Drug: insulin aspart


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any insulin näive type 2 diabetic patient that able to use the drug as judged by the investigator Exclusion Criteria: In accordance with approved label
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br> | Drug: insulin detemir<br>* Start dose and frequency at the discretion of the physician following clinical practice<br>Drug: biphasic insulin aspart 30<br>* Start dose and frequency at the discretion of the physician following clinical practice<br>Drug: insulin aspart<br>* Start dose and frequency at the discretion of the physician following clinical practice<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c |  | at baseline visit and during 3, 6, 9 and 12 months | 
| Serious adverse drug reactions including major hypoglycaemic events |  | during 12 months of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of serious adverse drug reactions |  | during 12 months of treatment | 
| Number of all major (daytime and nocturnal) hypoglycaemic events |  | during 12 months of treatment | 
| Number of all minor (daytime and nocturnal) hypoglycaemic events |  | During 4 weeks prior to each study visit | 
| Weight (BMI) change |  | At 6 and 12 months | 
| Variability in fasting blood glucose values and average (mean) fasting blood glucose level |  | At baseline visit and after 6 and 12 months treatment | 
| Average post-prandial blood glucose level (2h after dinner) |  | At baseline visit and after 6 and 12 months treatment | 
| Quality of Life (QoL) as assessed by patient questionnaire |  | At baseline and the end of 6 and 12 months treatment |
Open Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus treated with Biguanide.

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: Miglitol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetic patients with Biguanide treatment Criteria for postprandial plasma glucose and HbA1c are met Exclusion Criteria: Type 1 diabetes Patients treated with other antidiabetic drugs or Insulin

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 69 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Miglitol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
alpa-glucosidase inhibitor,Biguanide
Wii Balance Board in Dizziness

Study Overview
=================
Brief Summary
-----------------
Patients with dizziness presently undergo physical therapy rehabilitation. Our study will study whether Wii Balance Board made by Nintendo Inc. will be helpful in patients with dizziness. They will undergo dizziness evaluation to quantify their dizziness.

Official Title
-----------------
A Pilot Study to Assess the Usefulness of the Wii Balance Board for Dizziness

Conditions
-----------------
Dizziness

Intervention / Treatment
-----------------
* Other: Wii Balance Board


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Abnormal posturography exam Exclusion Criteria: Pregnant Women and children

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Wii Balance Board<br>Wii Balance Board Training | Other: Wii Balance Board<br>* Participant will undergo Nintendo Wii Balance Board training for two months , five days a week for 30 minutes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Primary Care Management of Community-Acquired, Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to further the investigators' understanding of community acquired methicillin-resistant Staph Aureus (CA-MRSA) and treatment of it by developing real-world sustainable strategies consistent with existing guidelines on treatment of CA-MRSA from the Centers for Disease Control and Prevention (CDC) and test these strategies in busy primary care settings.

Official Title
-----------------
Management by Primary Care Clinicians of Patients Suspected of Having Community-Acquired, Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections

Conditions
-----------------
Methicillin-Resistant Staphylococcus Aureus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients presenting at a primary care clinic who have a skin or soft tissue infection. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Historical<br> | |
| Prospective<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physician Behavior Change | Intervention in practice for guideline-concordant care of CA MRSA | Throughout study participation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
primary health care
The Effect of Pregabalin on Pain of Propofol Injection

Study Overview
=================
Brief Summary
-----------------
Pain is a common side effect of propofol injection. The purpose of this study was to compare the efficacy of pregabalin and lidocaine in reducing propofol injection pain.

Detailed Description
-----------------
In a randomized, double blind, prospective trial, 120 patients were allocated to one of three groups (each n=40) receiving intravenous lidocaine 40mg (group L), oral pregabalin 75 mg (group LP), and oral pregabalin 150 mg (group HP) as pretreatment, followed by injection of 25% of 2 mg/kg propofol. Pain was assessed by a four point scale (0=no, 1=mild, 2=moderate, 3=severe pain).

Official Title
-----------------
The Effect of Pregabalin on Pain of Propofol Injection

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: Lidocaine
* Drug: Pregabalin
* Drug: propofol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient underwent elective dental surgery. Exclusion Criteria: Patient with a history of adverse response to lidocaine or pregabalin, Patient with cardiovascular or respiratory disease, Patient who takes any sedatives, analgesics, or anticonvulsants within 24 hours before surgery.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group L<br>Lidocaine 40mg was given intravenously before injection of propofol | Drug: Lidocaine<br> <br> Drug: propofol<br> <br> |
| Active Comparator: Group LP<br>Pregabalin 75 mg was given orally 2 hour before surgery | Drug: Pregabalin<br> <br> Drug: propofol<br> <br> |
| Active Comparator: Group HP<br>Pregabalin 150 mg was given orally 2 hour before surgery | Drug: Pregabalin<br> <br> Drug: propofol<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Propofol injection pain | Thirty seconds after pretreatment, 25% of the total calculated dose of propofol (2 mg/kg) was administrated into a dorsal hand vein. Ten seconds after injection of propofol, pain was assessed on a four-point scale (0=none, 1 = mild, 2= moderate, 3= severe). | 10 seconds after injection of propofol | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
propofol, lidocaine, pregabalin
Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in male patients.

Official Title
-----------------
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Male Subjects With Recent Onset Atrial Fibrillation or Flutter

Conditions
-----------------
Atrial Fibrillation, Atrial Flutter

Intervention / Treatment
-----------------
* Drug: Tedisamil sesquifumarate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing to sign informed consent before screening examinations are performed and before the study drug is administered Males > 18 years of age Subjects with documented (60 second rhythm strip) symptomatic atrial fibrillation or flutter (duration > 3 hours and < 45 days) at the time of randomization Subjects who are in no distress and hemodynamically stable (supine systolic blood pressure > 90 mmHg and diastolic blood pressure < 105 mmHg) Exclusion Criteria: Acute myocardial infarction and cerebrovascular accidents Coronary and heart failure symptoms Life-threatening ventricular arrhythmias and electrocardiogram (ECG) abnormalities Electrolyte abnormalities Concurrent antiarrhythmic treatments

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tedisamil sesquifumarate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atrial fibrillation, atrial flutter, anti-arrhythmic agents, conversion to normal sinus rhythm
Predictors of de Novo Urge Urinary Incontinence After Photoselective Vaporization of the Prostate

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to investigate the incidence of de novo urge urinary incontinence after the photoselective vaporization of the prostate for benign prostatic hyperplasia using the validated overactive bladder symptom score, and to determine the predictors of de novo urge urinary incontinence following the photoselective vaporization of the prostate.

Conditions
-----------------
Urgency, Prostatic Hyperplasia, Urinary Incontinence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: men in whom 6-months follow-up data were available men who did not complain of urge urinary incontinence based on the OABSS (overactive symptom score): OABSS question 4 score of ≤ 1 Exclusion Criteria: previous prostate or bladder surgery a previous diagnosis of urethral stricture or prostate carcinoma or bladder cancer or neurogenic bladder disease

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| photoselective vaporization<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| de novo urge urinary incontinence at 6 months after surgery | de novo urge urinary incontinence: OABSS (overactive bladder symptom score) question 4 of ≥ 2 | 6 months postoperatively |
Mineral-Homeostasis in Continuous Renal Replacement Therapy

Study Overview
=================
Brief Summary
-----------------
Acute renal failure is a common complication in intensive care unit patients. In 10% of cases renal replacement therapy becomes necessary. Current devices have increase filter patency and efficacy. However, magnesium, calcium and phosphate are eliminated as well. However, the extend of this elimination hase not been quantified. Thus, we want to record retrospectively how often abnormal values for phosphate, magnesium and calcium occurred during routine renal replacement therapy in 2011 and 2012. prospectively evaluate the same parameters during routine treatment in 2013 and 2014

Official Title
-----------------
Phosphate, Magnesium and Calcium-Homeostasis in Patients With Acute Renal Failure and Continuous Renal Replacement Therapy

Conditions
-----------------
Acute Renal Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: intensive care unit patients with acute renal failure undergoing continuous renal replacement therapy older than 18 years of age Exclusion Criteria: age less than 18 years pregnancy contraindications against continuous renal replacement therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Retrospektive Cohort<br>Patients requiring renal replacement therapy from 2011 to 2012 on intensive care unit | |
| Prospektive Cohort<br>Patients requiring renal replacement on intensive care unit in 2013 and 2014 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of hypo-phosphate,-magnesium and calcaemia | Participants will be followed for the duration of ICU stay, an expected average of 28 days | approximately 28 days |